Treatment of hepatitis B virus: an update

被引：21
作者：
Ward, Haley [1 ]
Tang, Lydia [2 ]
Poonia, Bhawna [2 ]
Kottilil, Shyam [2 ]
机构：
[1] NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA
[2] Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, Baltimore, MD 21201 USA
来源：
FUTURE MICROBIOLOGY | 2016年 / 11卷 / 12期
关键词：
cccDNA; eradication; HBV; hepatitis B; Toll-like receptors; TLRs; ALPHA-GLUCOSIDASE INHIBITORS; CLOSED CIRCULAR DNA; PLASMACYTOID DENDRITIC CELLS; COMPLEX THERAPEUTIC VACCINE; ZINC-FINGER NUCLEASES; TERM-FOLLOW-UP; SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; IMMUNE-RESPONSES; IN-VIVO;
D O I：
10.2217/fmb-2016-0128
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse. Several novel therapeutic strategies are being researched and studied in clinical trials. Here we review these novel strategies to achieve sustained cure or elimination of HBV. These strategies include the targeting of the host or viral factors required for viral persistence as well as therapeutic vaccines.
引用
收藏
页码：1581 / 1597
页数：17
相关论文
共 168 条
  • [91] Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Marcellin, Patrick
    Gane, Edward
    Buti, Maria
    Afdhal, Nezam
    Sievert, William
    Jacobson, Ira M.
    Washington, Mary Kay
    Germanidis, George
    Flaherty, John F.
    Schall, Raul Aguilar
    Bornstein, Jeff Rey D.
    Kitrinos, Kathryn M.
    Subramanian, G. Mani
    McHutchison, John G.
    Heathcote, E. Jenny
    [J]. LANCET, 2013, 381 (9865) : 468 - 475
  • [92] TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
    Martin, Perrine
    Dubois, Clarisse
    Jacquier, Emilie
    Dion, Sarah
    Mancini-Bourgine, Maryline
    Godon, Ophelie
    Kratzer, Roland
    Lelu-Santolaria, Karine
    Evlachev, Alexei
    Meritet, Jean-Francois
    Schlesinger, Yasmin
    Villeval, Dominique
    Strub, Jean-Marc
    Van Dorsselaer, Alain
    Marchand, Jean-Baptiste
    Geist, Michel
    Brandely, Renee
    Findeli, Annie
    Boukhebza, Houda
    Menguy, Thierry
    Silvestre, Nathalie
    Michel, Marie-Louise
    Inchauspe, Genevieve
    [J]. GUT, 2015, 64 (12) : 1961 - 1971
  • [93] A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population
    Mbarek, Hamdi
    Ochi, Hidenori
    Urabe, Yuji
    Kumar, Vinod
    Kubo, Michiaki
    Hosono, Naoya
    Takahashi, Atsushi
    Kamatani, Yoichiro
    Miki, Daiki
    Abe, Hiromi
    Tsunoda, Tatsuhiko
    Kamatani, Naoyuki
    Chayama, Kazuaki
    Nakamura, Yusuke
    Matsuda, Koichi
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 (19) : 3884 - 3892
  • [94] Inhibition of hepatitis B virus in mice by RNA interference
    McCaffrey, AP
    Nakai, H
    Pandey, K
    Huang, Z
    Salazar, FH
    Xu, H
    Wieland, SF
    Marion, PL
    Kay, MA
    [J]. NATURE BIOTECHNOLOGY, 2003, 21 (06) : 639 - 644
  • [95] α-glucosidase inhibitors as potential broad based anti-viral agents
    Mehta, A
    Zitzmann, N
    Rudd, PM
    Block, TM
    Dwek, RA
    [J]. FEBS LETTERS, 1998, 430 (1-2) : 17 - 22
  • [96] Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase:: Therapeutic implications
    Mehta, A
    Carrouée, S
    Conyers, B
    Jordan, R
    Butters, T
    Dwek, RA
    Block, TM
    [J]. HEPATOLOGY, 2001, 33 (06) : 1488 - 1495
  • [97] Hepatitis B vaccines: Protective efficacy and therapeutic potential
    Michel, M. -L.
    Tiollais, P.
    [J]. PATHOLOGIE BIOLOGIE, 2010, 58 (04): : 288 - 295
  • [98] Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients
    Momeni, Mohammad
    Zainodini, Nahid
    Bidaki, Reza
    Hassanshahi, Gholamhossein
    Daneshvar, Hamid
    Khaleghinia, Mehdi
    Ebrahim, Maryam
    Karimi-Googheri, Masoud
    Askari, Azam
    Arababadi, Mohammad Kazemi
    Kennedy, Derek
    [J]. HUMAN IMMUNOLOGY, 2014, 75 (01) : 15 - 19
  • [99] Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
    Morrissey, DV
    Lockridge, JA
    Shaw, L
    Blanchard, K
    Jensen, K
    Breen, W
    Hartsough, K
    Machemer, L
    Radka, S
    Jadhav, V
    Vaish, N
    Zinnen, S
    Vargeese, C
    Bowman, K
    Shaffer, CS
    Jeffs, LB
    Judge, A
    MacLachlan, I
    Polisky, B
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (08) : 1002 - 1007
  • [100] HBsAg Seroclearance: Prognostic value for the response to treatment and the long-term outcome
    Moucari, R.
    Marcellin, P.
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 : S119 - S125
567891011121314